美国食品药品监督管理局(FDA)周一批准了渤健脊髓性肌萎缩症(SMA)药物Spinraza的更高剂量版本。此次获批对于这家美国制药商而言无疑是一剂强心针，该公司正面临着来自罗氏的口服药物Evrysdi以及诺华的基因疗法Zolgensma和Itvisma的日益激烈的竞争。新的治疗方案将在未来几周内在美国上市。28毫克规格的Spinraza定价约为15.2万美元，与12毫克规格的定价相同，50毫克规格定价约为27.1万美元。
美国食品药品监督管理局(FDA)周一批准了渤健脊髓性肌萎缩症(SMA)药物Spinraza的更高剂量版本。此次获批对于这家美国制药商而言无疑是一剂强心针，该公司正面临着来自罗氏的口服药物Evrysdi以及诺华的基因疗法Zolgensma和Itvisma的日益激烈的竞争。新的治疗方案将在未来几周内在美国上市。28毫克规格的Spinraza定价约为15.2万美元，与12毫克规格的定价相同，50毫克规格定价约为27.1万美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.